Tag: Tyrosine Kinase Inhibitors

Brands Classes DEA Class; Rx Common Brand Names; Zelboraf Antineoplastics, BRAF Kinase Inhibitor Description BRAF serine threonine kinase inhibitorUsed for the treatment of unresectable or metastatic melanoma and for the treatment of Erdheim-Chester disease in patients with V600E mutations of the BRAF geneSecondary malignancies have been reported Indications Indicated for treatment of unresectable or metastatic…

Brands Classes DEA Class; Rx Common Brand Names; Mekinist Antineoplastics, MEK Inhibitors Description MEK kinase inhibitor; confirm a BRAF V600 mutation using an FDA-approved testUsed as a single-agent in BRAF inhibitor-naive, advanced BRAF V600E or V600K mutation-positive melanoma, or in combination with dabrafenib for adjuvant or advanced therapy for BRAF V600E or V600K mutation-positive melanoma,…

Brands Classes DEA Class; Rx Common Brand Names; Sutent Antineoplastics, Tyrosine Kinase Inhibitor;  Antineoplastics, VEGF Inhibitor Description Oral, multi-targeted tyrosine kinase inhibitor with anti-angiogenic and anti-tumor activitiesUsed for gastrointestinal stromal tumor (GIST), renal cell carcinoma, and pancreatic neuroendocrine tumors (pNET)Black-box warning for hepatotoxicity; monitor hepatic function and adjust therapy accordingly Indications Indicated for treatment of…

Brands Classes DEA Class; Rx Common Brand Names; Nexavar Antineoplastics, Tyrosine Kinase Inhibitor;  Antineoplastics, VEGF Inhibitor Description Multi-kinase inhibitor targeting several intracellular and cell surface kinasesUsed for the treatment of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid cancer refractory to radioactive iodine treatmentDermatologic toxicities are among the most common adverse reactions associated with sorafenib…

Brands Classes DEA Class; Rx Common Brand Names; Votrient Antineoplastics, Tyrosine Kinase Inhibitor;  Antineoplastics, VEGF Inhibitor Description Oral multi-tyrosine kinase inhibitorFor advanced renal cell carcinoma and soft-tissue sarcomaSevere and fatal hepatotoxicity has been reported Indications Indicated for advanced renal cell carcinoma (RCC) Indicated for advanced soft tissue sarcoma (STS) who have received prior chemotherapy Contraindications…

Brands Classes DEA Class; Rx Common Brand Names; Tasigna Antineoplastics, Tyrosine Kinase Inhibitor Description An oral EGFR kinase inhibitorUsed for certain types of non-small cell lung cancerSerious adverse effects include QTc prolongation, neutropenia, and ILD/pneumonitis Indications Non-Small Cell Lung Cancer Adjuvant therapy Indicated as adjuvant therapy after tumor resection for non-small cell lung cancer (NSCLC)…

Brands Classes DEA Class; Rx Common Brand Names; Tasigna Antineoplastics, Tyrosine Kinase Inhibitor Description BCR-ABL tyrosine kinase inhibitorUsed in certain types of Philadelphia chromosome-positive chronic myelogenous leukemiaMay cause QT prolongation; sudden death has been reported Indications Indicated for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Contraindications Long QT syndrome, hypokalemia, hypomagnesemia Adverse…

Brands Classes DEA Class; Rx Common Brand Names; Gleevec Antineoplastics, Tyrosine Kinase Inhibitor;  PDGFR-alpha Inhibitors Description Oral BCR-ABL tyrosine kinase inhibitorUsed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia in adults and pediatric patients, and myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and malignant gastrointestinal…

Brands Classes DEA Class; Rx Common Brand Names; Zydelig Antineoplastics, PI3K Inhibitors Description Phosphatidylinositol 3-kinase inhibitorUsed in adults for the treatment of relapsed chronic lymphocytic leukemia in combination with rituximab and as a single-agent for the treatment of relapsed follicular lymphoma or small lymphocytic lymphoma following at least 2 prior therapiesBlack box warning for fatal…

Brands Classes DEA Class; Rx Common Brand Names; Imbruvica Antineoplastics, Tyrosine Kinase Inhibitor Description An oral Bruton’s tyrosine kinase (BTK) inhibitorUsed in adult patients with mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinemia and in adults and pediatric patients aged 1 year and older with chronic graft-versus-host diseaseSerious…

Brands Classes DEA Class; Rx Common Brand Names; Tarceva Antineoplastics, Tyrosine Kinase Inhibitor;  Antineoplastics, EGFR Inhibitor Description Oral epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)Used for the treatment of metastatic non-small cell lung cancer (NSCLC) with exon 19 deletions or exon 21 (L858R) substitution mutations as monotherapy, and for the treatment of locally advanced, unresectable,…

Brands Classes DEA Class; Rx Common Brand Names; Sprycel Antineoplastics, Tyrosine Kinase Inhibitor Description Oral multi-tyrosine kinase inhibitorUsed in adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia with resistance or intolerance to prior therapy; also used in pediatric patients with chronic-phase Ph+ CMLSevere myelosuppression has been reported Indications…

Brands Classes DEA Class; Rx Common Brand Names; Tafinlar Antineoplastics, BRAF Kinase Inhibitor Description BRAF kinase inhibitor; confirm presence of the BRAF V600 mutation using an FDA-approved testUsed as a single-agent in advanced BRAF V600 mutation-positive melanoma or in combination with trametinib for BRAF V600E mutation-positive solid tumorsMonitor patients who have glucose-6-phosphate dehydrogenase deficiency for…

Brands Classes DEA Class; Rx Common Brand Names; Gilotrif Antineoplastics, Tyrosine Kinase Inhibitor;  Antineoplastics, EGFR Inhibitor Description Oral tyrosine-kinase inhibitorUsed for certain types of metastatic non-small cell lung cancerWithhold afatinib for severe or prolonged diarrhea not responsive to anti-diarrheal agents Indications Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer Indicated for first-line treatment in…